Immune Myocarditis: Upper Abdominal Pain in Melanoma Patient – Nivolumab
Table of Contents
Published october 2, 2025
Understanding the Case
A recent case report details an unusual presentation of immune-related myocarditis – inflammation of the heart muscle triggered by immunotherapy – in a patient undergoing treatment for metastatic subungual melanoma. The patient initially presented with upper abdominal discomfort,a symptom that masked the underlying cardiac issue,highlighting the diagnostic challenges associated with immune checkpoint inhibitors.
The patient was being treated with nivolumab, a type of immunotherapy known as a PD-1 inhibitor. Nivolumab works by blocking the PD-1 protein,allowing the immune system to attack cancer cells. However, this immune activation can sometimes lead to immune-related adverse events (irAEs), affecting various organs, including the heart. Myocarditis is a rare but potentially life-threatening irAE associated with nivolumab and other checkpoint inhibitors.
Atypical Presentation and Diagnostic Challenges
What made this case particularly noteworthy was the atypical presentation. Instead of typical cardiac symptoms like chest pain or shortness of breath, the patient experienced upper abdominal discomfort. This led to an initial misdirection in diagnosis, emphasizing the importance of considering myocarditis in patients receiving nivolumab even with non-cardiac symptoms. Prompt recognition and management are crucial, as delayed treatment can lead to severe complications.
Subungual Melanoma and Metastatic Disease
Subungual melanoma,a rare form of melanoma that develops under the fingernails or toenails,often presents at a later stage due to delayed diagnosis. When this melanoma metastasizes – spreads to other parts of the body – treatment options become more limited, and immunotherapy like nivolumab is frequently enough employed. The case underscores the complexities of managing metastatic melanoma and the potential for unexpected side effects from treatment.
Clinical Implications and Vigilance
this case serves as a critical reminder for clinicians to maintain a high index of suspicion for myocarditis in patients receiving nivolumab, even in the absence of classic cardiac symptoms. Early diagnosis, often involving cardiac biomarkers, electrocardiograms (ECGs), and potentially cardiac magnetic resonance imaging (MRI), is essential for initiating appropriate management, which typically includes corticosteroids and supportive care. Continued monitoring and a thorough understanding of irAEs are vital for optimizing patient outcomes in the era of immunotherapy.